Literature DB >> 1659012

[Treatment of chronic occupational lead poisoning with dimercaptosuccinic acid (DMSA)].

P Grandjean1, I A Jacobsen, P J Jørgensen, S Lings, O Andersen.   

Abstract

2,3-dimercaptosuccinic acid (DMSA) mobilizes lead from superficial depots. In comparison with other chelating agents, DMSA has a high therapeutic index and has the additional advantage that it can be administered orally. We have used DMSA for treatment of chronic occupational lead poisoning in a 54-year old male with signs of neurotoxic effects. The treatment resulted in a rapid decrease in the blood-lead concentration, followed by a slow increase after the treatment and subsequent stabilization at a blood-lead level lower than prior to treatment. During the first course of treatment, almost 100 mumols lead was excreted in the urine. As a result of successive courses of treatments, the patient's condition was improved. However, during the third course of treatment, he developed a mucocutaneous rash which faded again after withdrawal of DMSA; this reaction was subsequently provoked by sub-therapeutic doses, and continued treatment was therefore cancelled. Only minor, reversible side effects of DMSA have hitherto been reported, and DMSA must therefore be regarded a promising agent for long-term, out-patient chelation treatment of chronic lead poisoning.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1659012

Source DB:  PubMed          Journal:  Ugeskr Laeger        ISSN: 0041-5782


  1 in total

1.  Combined administration of taurine and monoisoamyl DMSA protects arsenic induced oxidative injury in rats.

Authors:  Swaran J S Flora; Swapnila Chouhan; Gurusamy M Kannan; Megha Mittal; Harimohan Swarnkar
Journal:  Oxid Med Cell Longev       Date:  2008 Oct-Dec       Impact factor: 6.543

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.